Login to Your Account

Ablynx, Merck Ink Neuroscience Nanobody Deal for up to $590M

By Nuala Moran
Staff Writer

Wednesday, October 3, 2012
LONDON – Ablynx NV signed a €456.5 million (US$589.5 million) neuroscience deal with Merck & Co Inc., after demonstrating its nanobodies are able to modulate ion channels in a way that no other antibody constructs can manage.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription